newsfilter
← Latest News
GlobeNewswire·

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and